Combination Medical Therapies for Hidradenitis Suppurativa

The presentation discusses the use of combination medical therapies for hidradenitis suppurativa (HS), focusing on the need for evidence-based treatment plans particularly for patients with refractory disease or comorbid inflammatory conditions. Emphasizing the importance of combining immunosuppressive or immunomodulating drugs with standard treatments, the speaker highlights commonly utilized first-line therapies such as retinoids and hormonal agents, while stressing that antibiotics should primarily be reserved for flare-ups. The talk covers various biological therapies, including TNF inhibitors (like adalimumab and infliximab) and IL-17 and IL-23 inhibitors, recommending the early application of these drugs at maximum dosages to effectively manage inflammation and prevent disease progression. The speaker also introduces emerging therapies, including Janus kinase (JAK) inhibitors and novel small molecules, and discusses the potential for combination therapies as a future solution for HS management. Caution is advised due to the associated safety concerns and the need for individualized treatment plans. Overall, the presentation underlines the increasing therapeutic options available for HS and the excitement surrounding advancements in treatment approaches.